Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.

摘要: Scintigraphy with ['"In-diethylenetriamine pentaacetic acid°-DPhe']-octreotide (DTPAOC) is used to demonstrate neuroendocrine and other somatostatin-receptor-positive tumors. Despite encouraging results, this "'In-labeled compound not well suited for peptide-receptor-mediated radiotherapy of somatosta tin-receptor-positive Another somatostatin analog, [1,4,7,10-tetraazacyclododecane-N,N',N",N'"-tetraacetic acid0, D-Phe1, Tyr3]-octreotide (DOTATOC), can be labeled the AŸ-emitter 90Yin a stable manner. Methods: We compared distribution, kinetics dosimetry 111ln-DTPAOC '"InDOTATOC in eight patients predict outcomes these parameters who will treated ^Y-DOTATOC. Results: Serumradioactivity levelsforthe radiopharmaceuticals did differ significantly 2-24 h after injection (P > 0.05). Up 2 postinjection they were slightly, but significantly, lower administration '"In-DOTATOC 0.05), although three four whom tumor uptake could calculated, it was higher '"In-DOTATOC. Conclusion: The distribu tion excretion pattern resembles that 111ln-DTPAOC, organs most tumors 11tln-DOTATOC.If ^YDOTATOCshows an similar 111ln-DOTATOC, promising radiopharmaceutical peptide-receptor-medi ated